|
US2019365788A1
|
|
Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
|
|
WO2016189055A1
|
|
Nucleotides for the treatment of cancer
|
|
WO2016188943A1
|
|
Nucleotides for the treatment of cancer
|
|
KR20170005492A
|
|
Nucleoside derivatives for the treatment of cancer
|
|
EP3131914A1
|
|
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
US2017066779A1
|
|
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
EP3074399A1
|
|
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
|
US2017029456A1
|
|
Nucleotides for the treatment of liver cancer
|
|
US2016280729A1
|
|
Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
|
|
EP3027636A1
|
|
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
US2014364446A1
|
|
1′,4′-thio nucleosides for the treatment of HCV
|
|
EP2909223A1
|
|
Dinucleotide compounds for hcv infection
|
|
EA030189B1
|
|
2'-chloro nucleoside analogs for hcv infection
|
|
US2014086873A1
|
|
Esters and malonates of SATE prodrugs
|
|
MD20140134A2
|
|
D-amino acid compounds for the treatment of liver diseases
|
|
EP2852605A1
|
|
3',5'-cyclic phosphate prodrugs for hcv infection
|
|
EP2852604A1
|
|
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
EP2755983A1
|
|
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
|
EP2552203A1
|
|
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
EP2461811A1
|
|
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
